There were 44 patients with biopsy-proven NASH

Posted on June 20, 2018 by admin

There were 44 patients with biopsy-proven NASH Galunisertib mw in the elderly patients group and 412 patients with biopsy-proven NASH in the nonelderly patients group (Table 3). Compared to nonelderly patients with NASH, elderly patients with NASH had higher rates of advanced fibrosis (52% versus 35%, P = 0.03), as well as other features suggestive

of severe liver disease including ballooning degeneration, acidophil bodies, megamitochondria, and Mallory-Denk bodies (P ≤ 0.05 for each) (Table 3). In contrast, compared to nonelderly patients with NASH, elderly patients had lesser degrees of steatosis (48% versus 67% >33% steatosis, P = 0.01). We then investigated the characteristics of the presence of NASH in elderly patients by comparing how it differs from those without NASH in this age group (Supporting Table 1). Elderly patients with NASH had significantly higher

www.selleckchem.com/products/Y-27632.html average values for AST (70 ± 48 versus 38 ± 12 U/L, P < 0.001), ALT (75 ± 49 versus 49 ± 21 U/L, P = 0.006), and GGT (88 ± 82 versus 49 ± 44 U/L, P = 0.02). In addition, the average platelet count was lower (204 ± 59 versus 254 ± 71 ×1,000/mm3, P = 0.02) (Supporting Table 1). The mean APRI score was significantly higher in elderly patients with NASH compared to elderly patients without NASH (0.8 ± 0.7 versus 0.4 ± 0.3, P < 0.001). There was no significant difference in steatosis and degree of lobular inflammation between those with and without NASH. However, as would be expected, NASH patients were more likely to have ballooning degeneration. In addition, Mallory-Denk bodies were present in 72% of NASH patients, while these were absent in those who did not have NASH (P < 0.001) (Supporting Table 1). The NAFLD activity score (NAS) as indicated Farnesyltransferase by the percentage of patients with NAS ≥5 was higher in elderly patients with NASH compared to elderly patients without NASH (70% versus 18%, P < 0.001). Elderly patients with NASH were more likely to have advanced fibrosis compared to elderly patients who

did not have NASH (52% versus 24%, P = 0.05) (Supporting Table 1). Independent predictors of NASH among elderly patients determined from multivariable-adjusted logistic regression analyses were: younger age among this cohort with age ≥65 (OR = 0.65, 95% CI: 0.46-0.91, P = 0.01); higher AST value (OR = 1.12, 95% CI: 1.03-1.22, P = 0.007), and lower platelet count (OR = 0.98, 95% CI: 0.96-1.00, P = 0.02) (Table 4). Characteristics of elderly patients with advanced fibrosis compared to those with stage 0-2 fibrosis are shown in Supporting Table 2. Patients with advanced fibrosis were more likely to have metabolic syndrome, higher average BMI, and increased fasting serum insulin, HOMA-IR, INR, and AST/ALT ratio. In addition, patients with advanced fibrosis had lower mean platelet count, total cholesterol, and LDL cholesterol levels.

Related posts:

1. Studies have proven the 5-year survival fee was 55% for patients with favorable
2. 7 versus 22 1) than patients who never received low-dose corticos
3. Eleven patients (55%) died, 9 patients (45%) are alive The 5 yea
4. In patients with EGFR immunohistochemistry-positive tumours, chemotherapy did no
5. 05 level of significance The characteristics of the 221 patients

This entry was posted in Antibody. Bookmark the permalink.